1. Academic Validation
  2. Developing irreversible inhibitors of the protein kinase cysteinome

Developing irreversible inhibitors of the protein kinase cysteinome

  • Chem Biol. 2013 Feb 21;20(2):146-59. doi: 10.1016/j.chembiol.2012.12.006.
Qingsong Liu 1 Yogesh Sabnis Zheng Zhao Tinghu Zhang Sara J Buhrlage Lyn H Jones Nathanael S Gray


  • 1 Department of Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA.

Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large number of kinases may represent therapeutically relevant targets. To date, the majority of clinical and preclinical kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases. Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacological specificity through mutation of the reactive cysteine residue. Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.

  • Cat. No.
    Product Name
    Research Area
  • HY-13319
    99.65%, JNK Inhibitor